Omilancor
Tier C — Watch / tradeOmilancor
Targets：LANCL2
Indications (approved)：Ulcerative colitis, Crohn's disease, Eosinophilic oesophagitis
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| BT-11 | 1912399-75-7 | - |
| BT-11-001 | 144493-38-9 | 6-(1H-benzo[d]imidazol-2-yl)picolinic acid |
| BT-11-002 | 110-85-0Available | piperazine |
Frequently asked questions
What are the approved indications of Omilancor?
Approved indications include: Ulcerative colitis, Crohn's disease, Eosinophilic oesophagitis.
When does the Omilancor patent expire?
No public expiry year is available for Omilancor yet; this page updates once verified.
How many synthesis routes are recorded for Omilancor?
1 synthesis routes are recorded; the shortest is 1 steps with 30 mg (BT-11) total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Omilancor intermediates?
1 intermediate CAS of Omilancor are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Omilancor intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30